Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma

Gene expression profiling (GEP) has identified genes whose expression levels predict patient survival in diffuse large-B-cell lymphoma (DLBCL). Such discovery techniques generally require frozen samples unavailable for most patients. We developed a quantitative nuclease protection assay to measure expression levels of prognostic DLBCL genes using formalin-fixed, paraffin-embedded (FFPE) tissue. FFPE tissue was sectioned, permeabilized, denatured in the presence of specific probes, and hybridized to mRNA in situ. Nuclease subsequently destroyed non-hybridized probe. Alkaline hydrolysis freed mRNA-bound probes from tissue, which were transferred to ArrayPlates for probe capture and chemiluminescent quantification. We validated assay performance using frozen, fresh, and FFPE DLBCL samples, then used 39 archived DLBCL, previously microarray analyzed, to correlate GEP and ArrayPlate results. We compared old (>18 years) with new (<2 months) paraffin blocks made from previously frozen tissue from the original biopsy. ArrayPlate gene expression results were confirmed with immunohistochemistry for BCL2, BCL6, and HLA-DR, showing agreement between mRNA species and the proteins they encode. Assay performance was linear to ∼1 mg sample/well. RNase and DNase treatments demonstrated assay specificity for RNA detection, both fixed and soluble RNA detection. Comparisons were excellent for lysate vs snap-frozen vs FFPE (R2>0.98 for all comparisons). Coefficients of variation for quadruplicates on FFPE were generally <20%. Correlation between new and old paraffin blocks from the same biopsy was good (R2=0.71). Comparison of ArrayPlate to Affymetrix and cDNA microarrays showed reasonable correlations. Insufficient power from small sample size prevented successfully correlating results with patient survival, although hazard ratios trended the expected directions. We developed an assay to quantify expression levels of survival prediction genes in DLBCL using FFPE, fresh, or frozen tissue. While this technique cannot replace GEP for discovery, it indicates that expression differences identified by GEP can be replicated on a platform applicable to archived FFPE samples.

[1]  J. Fleiss Statistical methods for rates and proportions , 1974 .

[2]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[3]  R. Accolla Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets , 1983, The Journal of experimental medicine.

[4]  B. Efron The jackknife, the bootstrap, and other resampling plans , 1987 .

[5]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[6]  Ash A. Alizadeh,et al.  The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. , 1999, Cold Spring Harbor symposia on quantitative biology.

[7]  Lucila Ohno-Machado,et al.  Analysis of matched mRNA measurements from two different microarray technologies , 2002, Bioinform..

[8]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[9]  Meland,et al.  THE USE OF MOLECULAR PROFILING TO PREDICT SURVIVAL AFTER CHEMOTHERAPY FOR DIFFUSE LARGE-B-CELL LYMPHOMA , 2002 .

[10]  D. A. Morales,et al.  Multiplexed screening assay for mRNA combining nuclease protection with luminescent array detection. , 2002, Assay and drug development technologies.

[11]  I. Lossos,et al.  Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies , 2003, Leukemia.

[12]  J. Fleiss,et al.  The measurement of interrater agreement , 2004 .

[13]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[14]  Robin A Roberts,et al.  A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. , 2005, Blood.

[15]  John Quackenbush,et al.  Multiple-laboratory comparison of microarray platforms , 2005, Nature Methods.

[16]  Kenji Takami,et al.  Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression ArrayPlate assay. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[17]  Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line. , 2006 .

[18]  D.,et al.  Regression Models and Life-Tables , 2022 .